Methylergonovine Uses, Dosage, Side Effects and Interactions
Methergine
Methergine was the first methylergonovine product the FDA approved, in 1946. An FDA-approved generic with the same active ingredient is listed.
Methylergometrine
Methylergometrine is a brand name for methylergonovine. It is not in the FDA’s directory today; generic methylergonovine is.
Methylergonovine is a uterine-contracting medicine used after childbirth to manage uterine atony, bleeding (hemorrhage) and subinvolution of the uterus, and to control uterine bleeding during labor. It comes as a tablet and as an injection.
Quick links
Ask Anything About MethylergonovineType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Methylergonovine in Short
- Drug class Ergot Derivative How the FDA classifies it
What it treatsMethylergonovine is used after the placenta is delivered. It helps manage uterine atony (a uterus that is too relaxed), hemorrhage (heavy bleeding) and subinvolution (the uterus not shrinking back as it should).
- How you get it Prescription only
- Comes asTablet and injectionAvailable strengths
Tablet (by mouth)
- 0.2 mg
Injection (into a muscle, into a vein)
- 0.2 mg/mL
- Crushing or chewingSome forms are on our Do Not Crush list Listed: Methylergonovine (tablet)
- Important safety informationWarnings and precautions Read the warnings and precautions for your exact product.
- Supplements and herbs20 interact 1 major, 10 moderate and 9 minor
- What pharmacies pay
- Generic$5.70 a tablet
- Injections: no national price found
- Generic versionYes, FDA-approved Listed with the FDA, which does not mean every pharmacy stocks it
The Pharmacist’s Take
Methylergonovine (Methergine) is an ergot medicine that makes the uterus contract firmly after childbirth to cut bleeding and help it shrink back. It is an older standby, on the U.S. market since about 1946 with FDA-approved generics listed, and is most often a second option after oxytocin, the standard first choice. A short course is generally well tolerated, though strong cramping (like heavy afterpains) and nausea are common. The thing to watch is a sudden rise in blood pressure, which is why it is not for anyone with high blood pressure, toxemia (pregnancy-related high blood pressure) or a current pregnancy, and why a severe headache or chest pain needs help right away.
Key Takeaways From the HelloPharmacist Team
- Take the tablets 3 or 4 times a day for no more than one week after delivery; any injection is given by your care team.
- Store the tablets well apart from your baby’s medicines, and get emergency help if a newborn is ever given any by mistake.
- Avoid clarithromycin, ritonavir and antifungals like ketoconazole or itraconazole while taking it, and mention it whenever a new medicine is prescribed.
- Pause breastfeeding during the tablet course, discard milk made meanwhile, and wait at least 12 hours after the last dose before nursing.
Patient Information Guide for Methylergonovine
What It’s Used For
Methylergonovine is used after childbirth and during labor. Uses by product:
- Methergine tablets and Methylergonovine Maleate tablets: routine management of uterine atony, hemorrhage and subinvolution of the uterus after delivery of the placenta.
- Methylergonovine Maleate injection: the same uses after delivery of the placenta.
- Methylergonovine Maleate injection and tablets: control of uterine hemorrhage in the second stage of labor after delivery of the anterior shoulder, as listed in their labels.
How It Works
Methylergonovine acts directly on the smooth muscle of the uterus. It increases the tone, rate and strength of its rhythmic contractions. This produces a rapid, sustained tightening of the uterus. That shortens the third stage of labor and reduces blood loss.
Drug Class
Drug Class
- Ergot Derivative
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Ergot Derivative
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)None listed for Methylergonovine in the FDA’s index.
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Methylergonovine in the FDA’s index.
From our Patient Information GuideMethylergonovine acts directly on the smooth muscle of the uterus. It increases the tone, rate and strength of its rhythmic contractions. This produces a rapid, sustained tightening of the uterus. Read How Methylergonovine Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)- Ergolines
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- Ergot alkaloids
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
The injection and tablets are used differently.
- Injection: given into a muscle or slowly into a vein by a healthcare professional. It may be repeated every 2 to 4 hours if needed. Vein injection is not routine and is given over at least 60 seconds.
- Tablets: taken by mouth about 3 or 4 times a day after delivery, for up to 1 week.
Follow your prescriber's directions. Ask your pharmacist or prescriber what to do about a missed dose.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Methylergonovine Taken by Mouth
Bleeding and uterus problems after childbirth
For women after delivery
Usual dose 1 tablet (0.2 mg each) 3 or 4 times a day
- One tablet (0.2 mg each), 0.2 mg, orally 3 or 4 times daily in the puerperium for a maximum of 1 week
Also 1 week
Methylergonovine Injection
Bleeding and uterus problems after childbirth
Women during or after delivery · Injection into a muscle Usual dose 1 mL (0.2 mg) into a muscle
- 1 mL, 0.2 mg, intramuscularly after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium
- May be repeated as required, at intervals of 2 to 4 hours
Women during or after delivery · Injection into a vein Usual dose 1 mL (0.2 mg) into a vein
- 1 mL, 0.2 mg, intravenously, administered slowly over a period of no less than 60 seconds
Side Effects
The most common side effects are:
Common side effects
- High blood pressure, sometimes with headache or seizure
- Low blood pressure
- Abdominal pain (from the uterus contracting)
- Nausea
- Vomiting
- Abdominal pain from uterine contractions
When to get medical help
- Chest pain, or signs of a heart attack, which have been reported rarely
- Severe headache, seizure, or signs of stroke, which can come with a sudden rise in blood pressure
- Numbness, tingling or coldness in the hands or feet
- Shortness of breath, a very slow or fast heartbeat, or palpitations
- Signs of a serious allergic reaction, which have been reported rarely
- Any exposure of a newborn to this medicine (breathing trouble, seizures, bluish skin, low urine output): get emergency help
Warnings and Precautions
- Vein injection: it should not be given routinely into a vein because of the risk of sudden high blood pressure and stroke-type events.
- Heart disease: people with coronary artery disease or its risk factors may be more likely to have a heart attack from blood vessel spasm.
- Medication errors: newborns have been given the tablets by mistake, with breathing problems, seizures and bluish skin. Store it separately from newborn medicines.
- Breastfeeding: do not breastfeed during tablet treatment. Wait at least 12 hours after the last dose.
- Liver or kidney problems: use caution.
Interactions
Several medicines and substances can change how methylergonovine works or increase its risks.
- Strong and moderate CYP 3A4 inhibitors (clarithromycin, ritonavir, ketoconazole, itraconazole, fluconazole, fluvoxamine, nefazodone, grapefruit juice): should not be combined, due to the risk of blood vessel spasm with similar ergot medicines.
- Weak CYP 3A4 inhibitors (cilostazol, ranitidine): use with caution.
- Rifampin and nevirapine: likely to weaken its effect.
- Beta-blockers: may increase blood vessel narrowing.
- Halothane and methoxyflurane: may reduce its effect on the uterus.
- Nitroglycerin and other angina medicines: their effect may be reduced.
- Other vasoconstrictors, ergot alkaloids, prostaglandins: use with caution.
Interactions Listed in the FDA-Approved Label
From the Methylergonovine prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
-
Strong and moderate CYP 3A4 inhibitors For example: saquinavir, grapefruit juice, nefazodone, macrolide antibiotics such as troleandomycin and clarithromycin, ritonavir, indinavir, nelfinavir, ketoconazole, itraconazole, voriconazole, fluconazole, fluvoxamine, clotrimazoleWhat happensSerious events with similar ergot drugs and potent CYP 3A4 inhibitors have caused vasospasm leading to cerebral ischemia and/or ischemia of the extremities.What to doShould not be co-administered with methylergonovine.
-
Weak CYP 3A4 inhibitors For example: chlorzoxazone, cilostazol, ranitidineWhat happensThese may interact with methylergonovine through CYP 3A4.What to doAdminister with caution.
-
Strong CYP3A4 inducers For example: nevirapine, rifampinWhat happensLikely to decrease the pharmacological action of methylergonovine.
-
Beta-blockersWhat happensMay enhance the vasoconstrictive action of ergot alkaloids.What to doUse caution when used together.
-
Anesthetics (halothane, methoxyflurane)What happensMay reduce the oxytocic potency of methylergonovine.
-
Glyceryl trinitrate and other antianginal drugsWhat happensMethylergonovine causes vasoconstriction and can be expected to reduce the effect of these drugs.
-
Other vasoconstrictors, ergot alkaloids, or prostaglandinsWhat happensConcurrent use may interact with methylergonovine.What to doUse caution when used together.
Read the label’s full interactions text
Drug Interactions CYP 3A4 inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. Although there have been no reports of such interactions with methylergonovine alone, potent CYP 3A4 inhibitors should not be coadministered with methylergonovine. Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Less potent CYP 3A4 inhibitors should be administered with caution. Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with methylergonovine. CYP3A4 inducers Drugs (e.g. nevirapine, rifampicin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate tablets, USP. Beta-blockers Caution should be exercised when methylergonovine maleate tablets, USP are used concurrently with beta-blockers. Concomitant administration with beta-blockers may enhance the vasoconstrictive action of ergot alkaloids. Anesthetics Anesthetics like halothan and methoxyfluran may reduce the oxytocic potency of methylergonovine maleate tablets, USP. Glyceryl trinitrate and other antianginal drugs Methylergonovine maleate produces vasoconstriction and can be expected to reduce the effect of glyceryl trinitrate and other antianginal drugs.
Excerpted: the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- Do not use it with high blood pressure, toxemia, pregnancy or a known allergy to it.
- Tell your doctor about coronary artery disease, smoking, obesity, diabetes or high cholesterol.
- Use caution with liver or kidney problems.
- Do not breastfeed during tablet treatment. Discard milk made during that time and wait at least 12 hours after the last dose.
Overdose
Too much can cause nausea, vomiting, low urine output, abdominal pain, numbness and tingling in the hands and feet, and high blood pressure. In severe cases it can be followed by low blood pressure, slowed breathing, low body temperature, seizures and coma. Treatment is symptom-based, so get emergency help right away. Newborns who were given it by mistake needed urgent care.
Half-Life and How Your Body Processes It
After a vein injection, it moves quickly from the blood into body tissues. About 60% of an oral dose is absorbed. This is probably lower because of first-pass metabolism in the liver. Muscle injection absorption is higher (78% during delivery), and about 25% greater than the tablet. Tablets reach peak blood levels in about 1 hour, though absorption can be slower in postpartum women (about 3 hours). The average half-life after a muscle injection is about 3.4 hours (range 1.5 to 12.7 hours).
Storage
STORE AND DISPENSE Tablets: Store below 25°C (77°F); in a tight, light-resistant container.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Supplements and Herbs That Interact With Methylergonovine
From the licensed clinical database we use, rolled up per supplement, most serious first.20 supplements and herbal products have documented interactions with Methylergonovine in the licensed clinical database we use.
Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.
- 1Major
- 10Moderate
- 9Minor
- ACTIVATED CHARCOALMajor
- COFFEE CHARCOALModerate
- EPHEDRAModerate
- ERGOTModerate
- EUROPEAN MANDRAKEModerate
- GLUCOMANNANModerate
- GUAR GUMModerate
- GUM ARABICModerate
Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Methylergonovine: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Methylergonovine — the kind of thing our pharmacy team would talk through with you at the counter.
What is methylergonovine used for?
How long does methylergonovine take to work?
How long do I take the tablets?
Can I breastfeed while taking methylergonovine?
What side effects should I expect, and which are urgent?
Are there medicines or foods I should avoid with methylergonovine?
Is methylergonovine available over the counter?
When was methylergonovine first available?
Who makes methylergonovine?
What is the brand name of methylergonovine?
What is the generic name of Methergine?
What drug class is methylergonovine?
Is there a generic version of methylergonovine?
What strengths does methylergonovine come in?
How much does methylergonovine cost?
Is there a methylergonovine shortage?
Where can I read the methylergonovine prescribing information (package insert)?
Can you crush methylergonovine?
Is methylergonovine gluten free?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Methylergonovine
Skip the scrolling. Ask in your own words and get an answer from Methylergonovine’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Methylergonovine’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Methylergonovine on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, as soon as they can.Methylergonovine Forms and Strengths (How It Comes)
Methylergonovine comes in 2 dose forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Methylergonovine inactive ingredients by manufacturer.
Tablet
How this form is used
- Methergine tablets are used after delivery of the placenta to manage uterine atony, hemorrhage and subinvolution of the uterus.
- Methylergonovine Maleate tablets are used to control uterine hemorrhage in the second stage of labor after delivery of the anterior shoulder.
- Methergine tablets are taken by mouth 3 or 4 times daily after delivery, for a maximum of 1 week.
- Methylergonovine Maleate tablets are taken by mouth 3 or 4 times daily in the puerperium, for a maximum of 1 week.
- Do not breastfeed during treatment with Methylergonovine Maleate tablets, and wait at least 12 hours after the last dose.
Injection
How this form is used
- Methylergonovine Maleate injection is used after delivery of the placenta to manage uterine atony, hemorrhage and subinvolution of the uterus.
- Methylergonovine Maleate injection is used to control uterine hemorrhage in the second stage of labor after delivery of the anterior shoulder.
- Methylergonovine Maleate injection can be given into a muscle, and may be repeated at intervals of 2 to 4 hours if required.
- Methylergonovine Maleate injection given into a vein should be given slowly over no less than 60 seconds, and is not routinely given this way.
- Methylergonovine Maleate injection should be checked visually for particles and discoloration before use.
Methylergonovine on the U.S. Market: Products, Makers and Brands
How Methylergonovine appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
13 companies list 15 Methylergonovine product records with the FDA, mostly as tablet, injection; the earliest marketing or approval year on record is 1946. The one brand name in the directory today is Methergine; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How Widely Methylergonovine Is Used (Medicaid Data)
How many Methylergonovine prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Methylergonovine prescribed? Of the 1,682 medications we measure, Methylergonovine ranks #1,058 by Medicaid prescriptions — more than 37% of them.
Utilization by Methylergonovine product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
methylergonovine maleate 0.2 MG Oral Tablet Most dispensed
7 of 34 listed NDCs had Medicaid claims. RxNorm 996824
1 ML methylergonovine maleate 0.2 MG/ML Injection
3 of 10 listed NDCs had Medicaid claims. RxNorm 996828
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 10 of the 44 listed Methylergonovine NDCs had Medicaid claims.
Compare Methylergonovine Products
A representative set of FDA-listed product records for Methylergonovine — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 0.2 mg/mL | Intramuscular, Intravenous | American Regent, Inc. | ANDA | View NDC → |
| 0.2 mg/mL | Intravenous | Breckenridge Pharmaceutical, Inc. | ANDA | View NDC → |
| 0.2 mg/mL | Intravenous | Bryant Ranch Prepack × 2 listings | ANDA | View NDC → |
| 0.2 mg/mL | Intramuscular, Intravenous | HF Acquisition Co. LLC. DBA HealthFirst | ANDA | View NDC → |
| 0.2 mg/mL | Intravenous | HF Acquisition Co LLC, DBA HealthFirst | ANDA | View NDC → |
| 0.2 mg/mL | Intramuscular, Intravenous | Pharmacist Pharmaceutical, LLC | ANDA | View NDC → |
| 💊Tablet | ||||
| 0.2 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 0.2 mg | Oral | Amneal Pharmaceuticals NY LLC | ANDA | View NDC → |
| 0.2 mg | Oral | Granules Pharmaceuticals Inc. | ANDA | View NDC → |
| 0.2 mg | Oral | Lupin Pharmaceuticals,Inc. | ANDA | View NDC → |
| 0.2 mg | Oral | Major Pharmaceuticals | ANDA | View NDC → |
| 0.2 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 0.2 mg | Oral | Teva Pharmaceuticals USA, Inc. | ANDA | View NDC → |
| 0.2 mg | Oral | Volley Pharmaceuticals, LLC | ANDA | View NDC → |
Showing 15 of 15 products — FDA National Drug Code Directory. See every product, package size and price: browse all 15 Methylergonovine NDCs →
Methylergonovine Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Methylergonovine — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Methylergonovine are wrong drug administered, drug exposure during pregnancy, vomiting; about 90% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Methylergonovine in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Methylergonovine FDA Approval History
How Methylergonovine went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Methylergonovine was first approved by the FDA in 1946 (Brand: METHERGINE · Edison Theraps Llc); the first generic version was approved in 2008. It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Methylergonovine Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list 2 Methylergonovine recalls since July 2021. One of them is still ongoing and is listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Carton Label: MAJOR, Methylergonovine Maleate Tablets, USP, 0.2 mg, 20 TABLETS (2 x 10), Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, in 46268, NDC 0904-7282-10. Blister… Lots: Lots: N02327, expires: 09/2026; N02740, expires: 12/2026; N03069, expires: 08/2027. FDA record D-0609-2026 →
- Methylergonovine Maleate Tablets, USP, 0.2mg, 12-count bottle, Rx Only, Distributed by: Amneal Pharmaceuticals, LLC, Bridgewater, NJ 08807, NDC # 69238-1605-2. Lots: Lot #: BJ01922A, exp. date 03/2024 FDA record D-0477-2024 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Methylergonovine in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 2
- Strengths
- 3
- Forms in current FDA listings
- 2 of 2
RxCUI 6883 -
Dose form (SCDF) InjectionIn current FDA listings
RxCUI 1740921Its strength (SCD)-
1 mL methylergonovine maleate 0.2 mg/mL
RxCUI 996828
-
1 mL methylergonovine maleate 0.2 mg/mL
-
Dose form (SCDF) Oral TabletIn current FDA listings
RxCUI 372859Its 2 strengths (SCD)-
0.125 mg
RxCUI 248629 -
0.2 mg
maleate
RxCUI 996824
-
0.125 mg
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Methylergonovine Supply and Shortage Status
Whether Methylergonovine is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
What Methylergonovine Costs Pharmacies (NADAC Benchmark)
What pharmacies pay to buy Methylergonovine: the national average from CMS’s weekly NADAC survey, as of Nov 18, 2026. It is the pharmacy’s cost, not your price at the counter.
No national price was found for Methylergonovine injections, so the prices below are for the tablets only.
How the Pharmacy Price Has Changed
Pick a strength to see how its price has changed since Nov 2023.
For the generic 0.2 mg tablet, pharmacies paid an average of $5.70 per tablet as of Nov 18, 2026, up 26% from $4.52 a year earlier.
- What pharmacies pay now
- $5.70
- per tablet, as of Nov 18, 2026
- Last 4 weeks
- Up 12%
- from $5.07 on Oct 21, 2026
- Last 12 months
- Up 26%
- from $4.52 on Nov 19, 2025
- Lowest and highest since Nov 2023
- $4.35 to $14.57
- per tablet
See the numbers, month by month
| Month | Pharmacy price |
|---|---|
| Nov 2026 | $5.70 |
| Oct 2026 | $5.07 |
| Sep 2026 | $4.50 |
| Aug 2026 | $4.35 |
| Jul 2026 | $4.43 |
| Jun 2026 | $5.01 |
| May 2026 | $5.51 |
| Apr 2026 | $5.75 |
| Mar 2026 | $5.66 |
| Feb 2026 | $5.30 |
| Jan 2026 | $4.93 |
| Dec 2025 | $4.53 |
| Nov 2025 | $4.52 |
| Oct 2025 | $5.04 |
| Sep 2025 | $5.53 |
| Aug 2025 | $5.97 |
| Jul 2025 | $6.27 |
| Jun 2025 | $6.37 |
| May 2025 | $6.30 |
| Apr 2025 | $6.52 |
| Mar 2025 | $6.99 |
| Feb 2025 | $7.49 |
| Jan 2025 | $7.83 |
| Dec 2024 | $7.89 |
| Nov 2024 | $8.45 |
| Oct 2024 | $7.65 |
| Sep 2024 | $6.45 |
| Aug 2024 | $5.99 |
| Jul 2024 | $5.68 |
| Jun 2024 | $5.98 |
| May 2024 | $6.17 |
| Apr 2024 | $6.25 |
| Mar 2024 | $7.69 |
| Feb 2024 | $7.69 |
| Jan 2024 | $11.79 |
| Dec 2023 | $14.57 |
| Nov 2023 | $14.57 |
| Form | Strength | Version | What pharmacies pay | |
|---|---|---|---|---|
| Tablet · Oral | 0.2 mg | Generic | $5.70 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC). Each row spans the package sizes CMS priced; the generic and the brand are priced separately.
Methylergonovine Brand Names
Methylergonovine has 2 brand names on record: Methergine and Methylergometrine. Methergine is in the FDA’s product directory today; Methylergometrine is not. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Methylergonovine: Manufacturers and Labelers
13 companies list Methylergonovine products with the FDA. By number of product records, the largest are Bryant Ranch Prepack, HF Acquisition Co LLC, DBA HealthFirst, American Health Packaging. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Methylergonovine Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Granules Pharmaceuticals Inc. is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →